- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02977741
Olanzapine for the Treatment of Refractory Chronic Nausea and Vomiting
August 16, 2018 updated by: Johns Hopkins University
Prospective, observational study evaluating the effect of olanzapine for the treatment of refractory chronic nausea and vomiting.
Study Overview
Detailed Description
Patients will be identified who are seen in the Johns Hopkins Gastroenterology Clinic, suffer from chronic nausea and vomiting that is refractory to both prokinetic and antiemetic medications, and are being prescribed olanzapine for treatment of nausea and vomiting.
Patients who meet criteria will be enrolled and their gastrointestinal symptoms, quality of life, and psychological symptoms will be assessed by various questionnaires and followed over the course of 3 months.
Study Type
Observational
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Johns Hopkins University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Adult patients who are seen in the Johns Hopkins Center for Neurogastroenterology, have been identified by the healthcare provider (physician, nurse practitioner, physician assistant) as having refractory chronic nausea and vomiting that has failed a trial of typical treatments (both anti-emetics and pro kinetics), and who will be prescribed olanzapine for the treatment of chronic nausea and vomiting
Description
Inclusion Criteria:
- 18-65 years of age
- Able to communicate in English without aid of interpreter
Have chronic refractory nausea, meeting each of the following criteria:
- Baseline nausea and vomiting score on VAS of 25mm or greater
- Duration symptoms of at least 6 months (does not have to be contiguous)
- Intolerance to or inadequate response to prior treatment with both 1) ondansetron or another serotonin (5HT3) antagonist and 2) metoclopramide or domperidone
Exclusion Criteria:
- History of chemotherapy within the last year
- Current diagnosis of cancer
- Pregnant or breastfeeding
- For females, active efforts to conceive/become pregnant during the time of the study
- Chronic opioid use (3 times a week or greater use)
- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) elevation of greater than 2x upper limit of normal (within 3 months of enrollment)
- Cirrhosis
- Unable or unwilling to stop using metoclopramide while using olanzapine
- Concomitant use of other antipsychotics (e.g., haloperidol)
- Prolonged corrected QT interval (QTc) (>470ms for men and >480ms for women)
- History of life-threatening arrhythmia
- Hypokalemia (potassium <3.1) or hypomagnesemia (magnesium <1.2)
- Metabolic syndrome, defined as per Adult Treatment Panel III criteria
- Granulocytopenia (absolute neutrophil count <1500)
- History of tardive dyskinesia
- History of acute dystonic reaction to medications
- History of neuroleptic malignant syndrome
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Nausea and vomiting severity
Time Frame: 3 months
|
Effect of olanzapine on refractory nausea and vomiting as per changes in patient scoring of the severity of nausea and vomiting on a daily visual analog scale (VAS).
Scores range from 0-100, with higher scores indicating more severe symptoms.
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Severity of upper gastrointestinal symptoms
Time Frame: 3 months
|
The effect of olanzapine on severity of upper gastrointestinal symptoms, assessed by the NIH Patient-Reported Outcomes Measurement Information System (PROMIS) Gastrointestinal Symptom Scales questionnaire.
The questionnaire is 60-item GI symptom questionnaire covering 8 domains: Gastroesophageal reflux (13 items), disrupted swallowing (7 items), diarrhea (5 items), bowel incontinence/soilage (4 items), nausea and vomiting (4 items), constipation (9 items), belly pain (6 items), and gas/bloat/flatulence (12 items).
Higher scores indicate more severe symptoms.
A scoring service is used to convert the raw scores to a final T-score.
|
3 months
|
Quality of life and functional status
Time Frame: 3 months
|
The effect of olanzapine on quality of life and functional status, assessed by the EuroQol 5 Dimension (EQ-5D) questionnaire.
The EQ-5D descriptive system consists of five dimensions: Mobility, Self-care, Usual activities, Pain/discomfort, Anxiety/depression.
Scores range from 5-25, with higher scores indicating more severe symptoms/decreased quality of life.
|
3 months
|
Symptom-specific anxiety
Time Frame: 3 months
|
The effect of olanzapine on patient's overall gastrointestinal symptom-specific anxiety, assessed by the Visceral Sensitivity Index (VSI) questionnaire.
The VSI is an instrument to assess gastrointestinal-specific anxiety, the cognitive, affective, and behavioral response to fear of gastrointestinal sensations, symptoms, and the context in which these visceral sensations and symptoms occur.
The questionnaire consists of 15 questions, each scored 1-6.
Total scores range from 15-90, with lower scores indicating more severe symptoms.
|
3 months
|
Presence of depression
Time Frame: 3 months
|
Presence of depression in participants both before initiating olanzapine and after starting olanzapine, assessed by the Patient Health Questionnaire (PHQ-4) at baseline, 1 month, and 3 months.
Total score is determined by adding together the scores for each of the 4 items.
Scores range from 0-12 and are rated as normal (0-2), mild depression (3-5), moderate depression (6-8), and severe depression (9-12).
|
3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2016
Primary Completion (ACTUAL)
December 1, 2017
Study Completion (ACTUAL)
December 1, 2017
Study Registration Dates
First Submitted
November 28, 2016
First Submitted That Met QC Criteria
November 28, 2016
First Posted (ESTIMATE)
November 30, 2016
Study Record Updates
Last Update Posted (ACTUAL)
August 20, 2018
Last Update Submitted That Met QC Criteria
August 16, 2018
Last Verified
August 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Signs and Symptoms, Digestive
- Nausea
- Vomiting
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Autonomic Agents
- Peripheral Nervous System Agents
- Antiemetics
- Gastrointestinal Agents
- Antipsychotic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Uptake Inhibitors
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Serotonin Agents
- Olanzapine
Other Study ID Numbers
- IRB00037144
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nausea
-
University of North Carolina, Chapel HillNational Institute of Dental and Craniofacial Research (NIDCR)CompletedPost-operative Nausea | Post-operative Vomiting | Nausea PersistentUnited States
-
Cukurova UniversityTarsus UniversityRecruitingNausea, Postoperative | Vomiting, Postoperative | APFEL RİSK SCORETurkey
-
MonoSol RxCompletedNausea With Vomiting Chemotherapy-Induced | Nausea and Vomiting, PostoperativeIndia
-
GlaxoSmithKlineCompletedPostoperative Nausea and Vomiting | Nausea and Vomiting, PostoperativeUnited States, Spain, Philippines, Israel, Hong Kong, Thailand, United Kingdom, Hungary, Slovenia, Norway, Denmark
-
Hoffmann-La RocheCompletedPost-Operative Nausea and VomitingUnited States
-
Cairo UniversityUnknownPost Operative Nausea and VomitingEgypt
-
Yonsei UniversityCompletedPost Operative Nausea and VomitingKorea, Republic of
-
AccentureCompletedPost-Operative Nausea and Vomiting (PONV)Australia
-
Mayo ClinicCompleted
-
Blokhin's Russian Cancer Research CenterRUSSCO/RakFondUnknownChemotherapy-induced Nausea and Vomiting | Nausea | Vomiting | Emesis | Nausea Post ChemotherapyRussian Federation
Clinical Trials on Olanzapine
-
Assistance Publique Hopitaux De MarseilleCompleted
-
Veterans Medical Research FoundationBristol-Myers SquibbCompleted
-
Eli Lilly and CompanyCompletedSchizophreniaUnited States, Puerto Rico, Spain, Romania, Canada, France, Argentina, Brazil, Greece, Portugal, Slovakia, Taiwan
-
Eli Lilly and CompanyCompletedSchizophrenic DisordersTurkey, Finland
-
Centre for Addiction and Mental HealthUniversity Health Network, TorontoRecruiting
-
Vanderbilt UniversityEli Lilly and CompanyCompleted
-
Alkermes, Inc.CompletedSchizophrenia | Alcohol Use DisorderUnited States, Bulgaria, Poland
-
Centre for Addiction and Mental HealthRecruitingInsulin Resistance | Type 2 Diabetes | Menstrual Cycle | AntipsychoticsCanada
-
Amani Hassan Abdel-WahabCompleted
-
The Mind Research NetworkCompleted